UnitedHealth Group Inc (NYSE:UNH) – Equities research analysts at Oppenheimer lifted their Q2 2019 earnings per share (EPS) estimates for shares of UnitedHealth Group in a report issued on Wednesday, April 17th, Zacks Investment Research reports. Oppenheimer analyst M. Wiederhorn now forecasts that the healthcare conglomerate will post earnings per share of $3.48 for the quarter, up from their prior forecast of $3.39. Oppenheimer currently has a “Outperform” rating and a $305.00 target price on the stock. Oppenheimer also issued estimates for UnitedHealth Group’s Q3 2019 earnings at $3.81 EPS, Q4 2019 earnings at $3.68 EPS, FY2019 earnings at $14.70 EPS, Q1 2020 earnings at $4.07 EPS, Q2 2020 earnings at $4.00 EPS, Q3 2020 earnings at $4.37 EPS and FY2020 earnings at $16.67 EPS.
A number of other research analysts have also commented on UNH. Zacks Investment Research lowered shares of UnitedHealth Group from a “buy” rating to a “hold” rating in a research note on Saturday. Bank of America restated a “buy” rating and issued a $290.00 price objective (down from $320.00) on shares of UnitedHealth Group in a research note on Wednesday, April 17th. SunTrust Banks dropped their price target on shares of UnitedHealth Group to $300.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. They noted that the move was a valuation call. Barclays dropped their price target on shares of UnitedHealth Group from $290.00 to $270.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 17th. Finally, ValuEngine lowered shares of UnitedHealth Group from a “hold” rating to a “sell” rating in a research note on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. UnitedHealth Group presently has an average rating of “Buy” and a consensus price target of $290.47.
UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings data on Tuesday, April 16th. The healthcare conglomerate reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.60 by $0.13. The company had revenue of $60.30 billion for the quarter, compared to analyst estimates of $59.72 billion. UnitedHealth Group had a net margin of 5.45% and a return on equity of 25.07%. UnitedHealth Group’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.04 earnings per share.
Several institutional investors and hedge funds have recently made changes to their positions in UNH. Oregon Public Employees Retirement Fund lifted its stake in shares of UnitedHealth Group by 50,446.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 53,349,795 shares of the healthcare conglomerate’s stock valued at $214,000 after buying an additional 53,244,249 shares during the period. Norges Bank purchased a new position in shares of UnitedHealth Group during the fourth quarter valued at approximately $2,343,175,000. BlackRock Inc. lifted its stake in shares of UnitedHealth Group by 3.1% during the fourth quarter. BlackRock Inc. now owns 69,831,381 shares of the healthcare conglomerate’s stock valued at $17,396,391,000 after buying an additional 2,123,417 shares during the period. Rehmann Capital Advisory Group lifted its stake in shares of UnitedHealth Group by 26,088.2% during the third quarter. Rehmann Capital Advisory Group now owns 1,723,185 shares of the healthcare conglomerate’s stock valued at $6,477,000 after buying an additional 1,716,605 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in shares of UnitedHealth Group by 38.4% during the first quarter. Janus Henderson Group PLC now owns 5,525,999 shares of the healthcare conglomerate’s stock valued at $1,366,354,000 after buying an additional 1,532,738 shares during the period. 87.49% of the stock is currently owned by institutional investors and hedge funds.
In other UnitedHealth Group news, Director Frederick William Mcnabb III purchased 6,430 shares of UnitedHealth Group stock in a transaction on Wednesday, May 1st. The shares were bought at an average price of $233.21 per share, with a total value of $1,499,540.30. Following the completion of the acquisition, the director now directly owns 7,879 shares of the company’s stock, valued at $1,837,461.59. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO David S. Wichmann acquired 20,000 shares of UnitedHealth Group stock in a transaction that occurred on Friday, May 3rd. The shares were purchased at an average cost of $231.79 per share, for a total transaction of $4,635,800.00. Following the purchase, the chief executive officer now directly owns 904,367 shares of the company’s stock, valued at approximately $209,623,226.93. The disclosure for this purchase can be found here. Insiders sold 27,930 shares of company stock worth $6,746,683 in the last ninety days. Insiders own 0.87% of the company’s stock.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Further Reading: How to Track your Portfolio in Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.